Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-336682
Filing Date
2026-08-06
Accepted
2026-08-06 07:04:23
Documents
58
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q amlx-20260630.htm   iXBRL 10-Q 2694790
2 EX-31.1 amlx-ex31_1.htm EX-31.1 17604
3 EX-31.2 amlx-ex31_2.htm EX-31.2 17596
4 EX-31.3 amlx-ex31_3.htm EX-31.3 17596
5 EX-32.1 amlx-ex32_1.htm EX-32.1 9753
6 EX-32.2 amlx-ex32_2.htm EX-32.2 9751
7 EX-32.3 amlx-ex32_3.htm EX-32.3 9750
  Complete submission text file 0001193125-26-336682.txt   8126347

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20260630.xsd EX-101.SCH 891643
61 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20260630_htm.xml XML 1228449
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142 617-682-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41199 | Film No.: 261245894
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)